drugset / Trial / NCT01611480

Efficacy and Safety of a New Topical Formulation With Imiquimod (Limtop) Applied 1, 3 or 7 Times Weekly During 2 x 2 Weeks Treatment for Actinic Keratosis on the Head

NCT01611480

Phase 2 Completed Moberg Pharma AB

Summary

The aim is to evaluate efficacy and safety of three different dosing regimens of Limtop in a study involving 96 patients with actinic keratosis on the head or face.

Timeline

Start
Primary completion
2013-01
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Imiquimod Other / unclassified

Indications